CN115515642A - 抗cd56抗体-药物偶联物及其在治疗中的用途 - Google Patents

抗cd56抗体-药物偶联物及其在治疗中的用途 Download PDF

Info

Publication number
CN115515642A
CN115515642A CN202180017269.9A CN202180017269A CN115515642A CN 115515642 A CN115515642 A CN 115515642A CN 202180017269 A CN202180017269 A CN 202180017269A CN 115515642 A CN115515642 A CN 115515642A
Authority
CN
China
Prior art keywords
antibody
drug conjugate
drug
ser
mmae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180017269.9A
Other languages
English (en)
Chinese (zh)
Inventor
鲁多维奇·琼
克里斯汀·巴尔图斯
奥黛丽·德格兰奇
安托万·图泽
蒂博·克瓦雷克
瓦蕾莉·莱布隆德
马赫塔布·萨米米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mcsaff Internal Tumor Co
Original Assignee
Mcsaff Internal Tumor Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcsaff Internal Tumor Co filed Critical Mcsaff Internal Tumor Co
Publication of CN115515642A publication Critical patent/CN115515642A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180017269.9A 2020-02-27 2021-02-26 抗cd56抗体-药物偶联物及其在治疗中的用途 Pending CN115515642A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR2001974A FR3107648B1 (fr) 2020-02-27 2020-02-27 conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie
FRFR2001974 2020-02-27
PCT/FR2021/050332 WO2021170961A1 (fr) 2020-02-27 2021-02-26 Conjugués anticorps-médicament anti-cd56 et leur utilisation en thérapie

Publications (1)

Publication Number Publication Date
CN115515642A true CN115515642A (zh) 2022-12-23

Family

ID=71894885

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180017269.9A Pending CN115515642A (zh) 2020-02-27 2021-02-26 抗cd56抗体-药物偶联物及其在治疗中的用途

Country Status (8)

Country Link
US (2) US20230144142A1 (https=)
EP (1) EP4110405A1 (https=)
JP (1) JP2023515845A (https=)
CN (1) CN115515642A (https=)
AU (1) AU2021227413A1 (https=)
CA (1) CA3166699A1 (https=)
FR (1) FR3107648B1 (https=)
WO (1) WO2021170961A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3096259B1 (fr) * 2019-05-20 2023-12-15 Mc Saf conjugués anticorps-médicament et leur utilisation en thérapie
FR3131835B1 (fr) * 2022-01-17 2025-11-21 Mc Saf Procédé de préparation de conjugués anticorps-médicament
FR3131836B1 (fr) * 2022-01-17 2025-05-23 Mc Saf Conjugués anticorps-médicament pour utilisation thérapeutique
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025149947A1 (en) * 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105592859A (zh) * 2013-07-11 2016-05-18 图尔大学 新型抗体-药物缀合物以及其在疗法中的用途
CN107744592A (zh) * 2017-09-15 2018-03-02 四川大学 抗cd56抗体与海兔毒素偶联复合物及其制备方法和用途
US20180214568A1 (en) * 2015-07-31 2018-08-02 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting cd56-positive tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104640572B (zh) * 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物，偶联方法，及其用途
WO2013177062A2 (en) * 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
CN107715119B (zh) * 2017-09-15 2020-11-10 四川大学 抗cd56抗体与多卡霉素偶联复合物及其制备方法和用途
SG11202006510XA (en) * 2018-01-08 2020-08-28 Regeneron Pharma Steroids and antibody-conjugates thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105592859A (zh) * 2013-07-11 2016-05-18 图尔大学 新型抗体-药物缀合物以及其在疗法中的用途
US20180214568A1 (en) * 2015-07-31 2018-08-02 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting cd56-positive tumors
CN107744592A (zh) * 2017-09-15 2018-03-02 四川大学 抗cd56抗体与海兔毒素偶联复合物及其制备方法和用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HANS HENNING VON HORSTEN等: ""Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase"", 《GLYCOBIOLOGY》, vol. 20, no. 12, 15 July 2010 (2010-07-15), pages 1607 - 1618 *
LIN YU等: ""Preparation and anti-cancer evaluation of promiximab-MMAE, an anti-CD56 antibody drug conjugate, in small cell lung cancer cell line xenograft models"", 《JOURNAL OF DRUG TARGETING》, vol. 26, no. 10, 13 April 2018 (2018-04-13), pages 905 - 912, XP055743269, DOI: 10.1080/1061186X.2018.1450413 *
YANG FENG等: ""Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes"", 《MABS》, vol. 8, no. 4, 24 February 2016 (2016-02-24), pages 799 - 810, XP055308031, DOI: 10.1080/19420862.2016.1155014 *

Also Published As

Publication number Publication date
US20230144142A1 (en) 2023-05-11
WO2021170961A1 (fr) 2021-09-02
FR3107648B1 (fr) 2022-03-18
FR3107648A1 (fr) 2021-09-03
EP4110405A1 (fr) 2023-01-04
AU2021227413A1 (en) 2022-10-20
JP2023515845A (ja) 2023-04-14
US20230405140A1 (en) 2023-12-21
CA3166699A1 (fr) 2021-09-02

Similar Documents

Publication Publication Date Title
CN115515642A (zh) 抗cd56抗体-药物偶联物及其在治疗中的用途
JP7696635B2 (ja) 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート
TWI662968B (zh) 配體－細胞毒性藥物偶聯物、其製備方法及其應用
KR20240082348A (ko) 항체, 이의 항체-약물 접합체 및 이의 용도
CN113677372A (zh) 可活化免疫检查点抑制剂和经缀合可活化抗体的组合疗法
JP2021513844A (ja) グリピカン３抗体およびそのコンジュゲート
KR20200120728A (ko) 항-메소텔린 항체 및 이의 항체 약물 콘쥬게이트
BR112020004231A2 (pt) anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
KR20180016724A (ko) Cd123 항체 및 이의 접합체
KR20160047567A (ko) 조작된 항-dll3 접합체 및 사용 방법
CN105849126A (zh) 抗trop2抗体－药物偶联物
CN106661124A (zh) 抗叶酸受体α(FRA)抗体‑药物缀合物及其使用方法
US10112999B2 (en) Anti-PRLR antibody-drug conjugates (ADC) and uses thereof
JP2022533854A (ja) 抗体－薬物コンジュゲート、及び、治療におけるその使用
KR20250137203A (ko) 항체 약물 접합체
CN113453724B (zh) 基于磺酰基马来酰亚胺的连接子和相应的偶联物
CN119604314A (zh) 抗gd2抗体、免疫偶联物及其治疗用途
JP2018515457A (ja) カリケアマイシン構築物および使用方法
WO2018052789A1 (en) Monoclonal antibodies specific to the plexin-semaphorin-integrin (psi) domain of ron for drug delivery and its application in cancer therapy
WO2026082125A1 (zh) 结合folr1的抗体、含有其的药物及其应用
WO2025185559A1 (zh) 抗FGFR2b抗体、其抗体药物偶联物及其用途
HK40094038A (zh) 抗体药物缀合物
HK40123391A (zh) 抗gd2抗体、免疫偶联物及其治疗用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221223

WD01 Invention patent application deemed withdrawn after publication